Arsenic trioxide downregulates specificity protein (Sp) transcription factors and inhibits bladder cancer cell and tumor growth

Experimental Cell Research

Volumn 316, Issue 13, 2010, Pages 2174-2188

  Jutooru, Indira ^a   Chadalapaka, Gayathri ^a   Sreevalsan, Sandeep ^a   Lei, Ping ^b   Barhoumi, Rola ^a   Burghardt, Robert ^a   Safe, Stephen ^a,b  

^a TEXAS A AND M UNIVERSITY   (United States)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

Anticancer activity; Arsenic trioxide; ROS; Sp repression

Indexed keywords

ARSENIC TRIOXIDE; CYCLIN D1; DITHIOTHREITOL; EPIDERMAL GROWTH FACTOR RECEPTOR; GLUTATHIONE; HYDROGEN PEROXIDE; PEROXIDE; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; SURVIVIN; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP3; TRANSCRIPTION FACTOR SP4; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER INHIBITION; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; FEMALE; GENE CONTROL; GENE REPRESSION; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; NUDE MOUSE; OXIDATIVE STRESS; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

MUS;

EID: 77953812438     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2010.04.027     Document Type: Article

References (55)

1. Klaassen C.D. Heavy metals and heavy-metal antagonists. Goodman & Gilman's The Pharmacological Basis of Therapeutics 1996, 1649-1672. McGraw-Hill, New York. J.G. Hardman, A.G. Gilman, L.E. Limbird (Eds.).
2. Dilda P.J., Hogg P.J. Arsenical-based cancer drugs. Cancer Treat. Rev. 2007, 33:542-564.
3. Miller W.H., Schipper H.M., Lee J.S., Singer J., Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res. 2002, 62:3893-3903.
4. Chan P.C., Huff J. Arsenic carcinogenesis in animals and in humans: mechanistic, experimental, and epidmeiological evidence. J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev. 1997, C15:83-122.
5. Zhang P., Wang S.Y., Hu X.H. Arsenic trioxide treated 72 cases of acute promyelocytic leukemia. Chin. J. Hematol. 1996, 17:58-62.
6. Sun H.D., Ma L., Hu X.C., Zhang T.D. Ai-Lin 1 treated 32 cases of acute promyelocytic leukemia. Chin. J. Integr. Chin. W Med. 1992, 12:170-172.
7. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997, 89:3354-3360.
8. Verstovsek S., Giles F., Quintas-Cardama A., Perez N., Ravandi-Kashani F., Beran M., Freireich E., Kantarjian H. Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?. Hematol. Oncol. 2006, 24:181-188.
9. Hu J., Fang J., Dong Y., Chen S.J., Chen Z. Arsenic in cancer therapy. Anticancer Drugs 2005, 16:119-127.
10. de Thé H., Chomienne C., Lanotte M., Degos L., Dejean A. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor a gene to a novel transcribed locus. Nature 1990, 347:558-561.
11. Borrow J., Goddard A.D., Sheer D., Solomon E. Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science 1990, 249:1577-1580.
12. 3 exerts dose-dependent dual effects on APL cells. Blood 1997, 89:3345-3353.
13. Shao W., Fanelli M., Ferrara F.F., Riccioni R., Rosenauer A., Davison K., Lamph W.W., Waxman S., Pelicci P.G., Lo C.F., Avvisati G., Testa U., Peschle C., Gambacorti-Passerini C., Nervi C., Miller W.H. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR a protein in acute promyelocytic leukemia cells. J. Natl. Cancer Inst. 1998, 90:124-133.
14. Larochette N., Decaudin D., Jacotot E., Brenner C., Marzo I., Susin S.A., Zamzami N., Xie Z., Reed J., Kroemer G. Arsenite induces apoptosis via a direct effect on the mitochondrial permeability transition pore. Exp. Cell Res. 1999, 249:413-421.
15. Shen Z.Y., Shen J., Cai W.J., Hong C., Zheng M.H. The alteration of mitochondria is an early event of arsenic trioxide induced apoptosis in esophageal carcinoma cells. Int. J. Mol. Med. 2000, 5:155-158.
16. Zhu X.H., Shen Y.L., Jing Y.K., Cai X., Jia P.M., Huang Y., Tang W., Shi G.Y., Sun Y.P., Dai J., Wang Z.Y., Chen S.J., Zhang T.D., Waxman S., Chen Z., Chen G.Q. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J. Natl. Cancer Inst. 1999, 91:772-778.
17. Kang Y.H., Lee S.J. The role of p38 MAPK and JNK in arsenic trioxide-induced mitochondrial cell death in human cervical cancer cells. J. Cell. Physiol. 2008, 217:23-33.
18. Chen Y.C., Lin-Shiau S.Y., Lin J.K. Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis. J. Cell. Physiol. 1998, 177:324-333.
19. Kumar P., Gao Q., Ning Y., Wang Z., Krebsbach P.H., Polverini P.J. Arsenic trioxide enhances the therapeutic efficacy of radiation treatment of oral squamous carcinoma while protecting bone. Mol. Cancer Ther. 2008, 7:2060-2069.
20. Xiao Y.F., Liu S.X., Wu D.D., Chen X., Ren L.F. Inhibitory effect of arsenic trioxide on angiogenesis and expression of vascular endothelial growth factor in gastric cancer. World J. Gastroenterol. 2006, 12:5780-5786.
21. Shen Z.Y., Shen J., Chen M.H., Wu X.Y., Wu M.H., Zeng Y. The inhibition of growth and angiogenesis in heterotransplanted esophageal carcinoma via intratumoral injection of arsenic trioxide. Oncol. Rep. 2003, 10:1869-1874.
22. Roboz G.J., Dias S., Lam G., Lane W.J., Soignet S.L., Warrell R.P., Rafii S. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 2000, 96:1525-1530.
23. Cheng Y., Chang L.W., Tsou T.C. Mitogen-activated protein kinases mediate arsenic-induced down-regulation of survivin in human lung adenocarcinoma cells. Arch. Toxicol. 2006, 80:310-318.
24. Jin H.O., Yoon S.I., Seo S.K., Lee H.C., Woo S.H., Yoo D.H., Lee S.J., Choe T.B., An S., Kwon T.J., Kim J.I., Park M.J., Hong S.I., Park I.C., Rhee C.H. Synergistic induction of apoptosis by sulindac and arsenic trioxide in human lung cancer A549 cells via reactive oxygen species-dependent down-regulation of survivin. Biochem. Pharmacol. 2006, 72:1228-1236.
25. 4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARa/PML proteins. Blood 1996, 88:1052-1061.
26. Ai Z., Lu W., Ton S., Liu H., Sou T., Shen Z., Qin X. Arsenic trioxide-mediated growth inhibition in gallbladder carcinoma cells via down-regulation of cyclin D1 transcription mediated by Sp1 transcription factor. Biochem. Biophys. Res. Commun. 2007, 360:684-689.
27. Han S.S., Kim K., Hahm E.R., Park C.H., Kimler B.F., Lee S.J., Lee S.H., Kim W.S., Jung C.W., Park K., Kim J., Yoon S.S., Lee J.H., Park S. Arsenic trioxide represses constitutive activation of NF-κB and COX-2 expression in human acute myeloid leukemia, HL-60. J. Cell. Biochem. 2005, 94:695-707.
28. Chadalapaka G., Jutooru I., Chintharlapalli S., Papineni S., Smith R., Li X., Safe S. Curcumin decreases specificity protein expression in bladder cancer cells. Cancer Res. 2008, 68:5345-5354.
29. Abdelrahim M., Safe S. Cyclooxygenase-2 inhibitors decrease vascular endothelial growth factor expession in colon cancer cells by enhanced degradation of Sp1 and Sp4 proteins. Mol. Pharmacol. 2005, 68:317-329.
30. Abdelrahim M., Samudio I., Smith R., Burghardt R., Safe S. Small inhibitory RNA duplexes for Sp1 mRNA block basal and estrogen-induced gene expression and cell cycle progression in MCF-7 breast cancer cells. J. Biol. Chem. 2002, 277:28815-28822.
31. Abdelrahim M., Smith R., Burghardt R., Safe S. Role of Sp proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells. Cancer Res. 2004, 64:6740-6749.
32. Higgins K.J., Abdelrahim M., Liu S., Yoon K., Safe S. Regulation of vascular endothelial growth factor receptor-2 expression in pancreatic cancer cells by Sp proteins. Biochem. Biophys. Res. Commun. 2006, 345:292-301.
33. Wang L., Wei D., Huang S., Peng Z., Le X., Wu T.T., Yao J., Ajani J., Xie K. Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin. Cancer Res. 2003, 9:6371-6380.
34. Yao J.C., Wang L., Wei D., Gong W., Hassan M., Wu T.T., Mansfield P., Ajani J., Xie K. Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin. Cancer Res. 2004, 10:4109-4117.
35. Chiefari E., Brunetti A., Arturi F., Bidart J.M., Russo D., Schlumberger M., Filetti S. Increased expression of AP2 and Sp1 transcription factors in human thyroid tumors: a role in NIS expression regulation?. BMC Cancer 2002, 2:35.
36. Hosoi Y., Watanabe T., Nakagawa K., Matsumoto Y., Enomoto A., Morita A., Nagawa H., Suzuki N. Up-regulation of DNA-dependent protein kinase activity and Sp1 in colorectal cancer. Int. J. Oncol. 2004, 25:461-468.
37. 2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res. 2007, 67:11001-11011.
38. Abdelrahim M., Baker C.H., Abbruzzese J.L., Safe S. Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J. Natl. Cancer Inst. 2006, 98:855-868.
39. Chintharlapalli S., Papineni S., Abdelrahim M., Abudayyeh A., Abudayyeh A., Jutooru I., Chadalapaka G., Wu F., Mertens-Talcott S.U., Vanderlaag K., Cho S.D., Smith R., Safe S. Oncogenic microRNA-27a is a target for anticancer agent methyl 2-cyano-3, 11-dioxo-18b-olean-1, 12-dien-30-oate in colon cancer cells. Int. J. Cancer 2009, 125:1965-1974.
40. Chintharlapalli S., Papineni S., Ramaiah S.K., Safe S. Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors. Cancer Res. 2007, 67:2816-2823.
41. Chou W.C., Chen H.Y., Yu S.L., Cheng L., Yang P.C., Dang C.V. Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood 2005, 106:304-310.
42. Chuang J.Y., Wu C.H., Lai M.D., Chang W.C., Hung J.J. Overexpression of Sp1 leads to p53-dependent apoptosis in cancer cells. Int. J. Cancer 2009, 125:2066-2076.
43. Yang C.H., Kuo M.L., Chen J.C., Chen Y.C. Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells. Br. J. Cancer 1999, 81:796-799.
44. Kroemer G., T.H.de Arsenic trioxide, a novel mitochondriotoxic anticancer agent?. J. Natl. Cancer Inst. 1999, 91:743-745.
45. Bouwman P., Philipsen S. Regulation of the activity of Sp1-related transcription factors. Mol. Cell. Endocrinol. 2002, 195:27-38.
46. Ammendola R., Mesuraca M., Russo T., Cimino F. Sp1 DNA binding efficiency is highly reduced in nuclear extracts from aged rat tissues. J. Biol. Chem. 1992, 267:17944-17948.
47. Oh J.E., Han J.A., Hwang E.S. Downregulation of transcription factor, Sp1, during cellular senescence. Biochem. Biophys. Res. Commun. 2007, 353:86-91.
48. Rickers A., Peters N., Badock V., Beyaert R., Vandenabeele P., Dorken B., Bommert K. Cleavage of transcription factor SP1 by caspases during anti-IgM-induced B-cell apoptosis. Eur. J. Biochem. 1999, 261:269-274.
49. Piedrafita F.J., Pfahl M. Retinoid-induced apoptosis and Sp1 cleavage occur independently of transcription and require caspase activation. Mol. Cell. Biol. 1997, 17:6348-6358.
50. Lu J., Chew E.H., Holmgren A. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:12288-12293.
51. Kajiguchi T., Yamamoto K., Iida S., Ueda R., Emi N., Naoe T. Sustained activation of c-jun-N-terminal kinase plays a critical role in arsenic trioxide-induced cell apoptosis in multiple myeloma cell lines. Cancer Sci. 2006, 97:540-545.
52. Morales A.A., Gutman D., Cejas P.J., Lee K.P., Boise L.H. Reactive oxygen species are not required for an arsenic trioxide-induced antioxidant response or apoptosis. J. Biol. Chem. 2009, 284:12886-12895.
53. Soucy N.V., Ihnat M.A., Kamat C.D., Hess L., Post M.J., Klei L.R., Clark C., Barchowsky A. Arsenic stimulates angiogenesis and tumorigenesis in vivo. Toxicol. Sci. 2003, 76:271-279.
54. Soucy N.V., Mayka D., Klei L.R., Nemec A.A., Bauer J.A., Barchowsky A. Neovascularization and angiogenic gene expression following chronic arsenic exposure in mice. Cardiovasc. Toxicol. 2005, 5:29-41.
55. Straub A.C., Clark K.A., Ross M.A., Chandra A.G., Li S., Gao X., Pagano P.J., Stolz D.B., Barchowsky A. Arsenic-stimulated liver sinusoidal capillarization in mice requires NADPH oxidase-generated superoxide. J. Clin. Invest. 2008, 118:3980-3989.